• Explore /
  • Poster
  • / Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): The BRIGHT study.

Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): The BRIGHT study.

Abstract Poster

Authors

null

David MacDonald

Dalhousie University, Halifax, NS, Canada

David MacDonald , Richard van der Jagt , John M. Burke , Brad S. Kahl , Peter Wood , Tim E. Hawkins , Mark Hertzberg , Yiu-Lam Kwan , David Simpson , Michael Craig , Kathryn S. Kolibaba , Samar Issa , Regina Clementi , Doreen M. Hallman , Mihaela C. Munteanu , Ling Chen , Ian Flinn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Clinical Trial Registration Number

NCT00877006

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8565)

DOI

10.1200/jco.2013.31.15_suppl.8565

Abstract #

8565

Poster Bd #

49D

Abstract Disclosures

Similar Posters

First Author: Ian Flinn

First Author: Ruemu Ejedafeta Birhiray

Poster

2023 ASCO Annual Meeting

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

First Author: Carrie Ho

First Author: David Belada